Continual reassessment methods in phase I trials of the combination of two drugs in oncology.

Most phase I trials in oncology use standard methods for treating successive groups of patients with increasing doses in order to determine the maximum tolerated dose (MTD). These methods have been criticized because they treat many patients at suboptimal dose levels, and do not provide an accurate estimation of the best dose level. Continual reassessment methods for the study of toxicity in single agent phase I trials have recently been advocated since they present many advantages over traditional methods. Although the advantages of these methods are recognized by most clinical investigators, their use is not widespread and their advantages have not yet been universally accepted. A maximum likelihood continual reassessment method was conducted retrospectively and compared to the originally planned standard method in a two drug combination phase I trial in order to study its applicability in this setting. Calculations from the binomial distributions and simulations were used for identifying the MTD, for the proportion of patients treated at the MTD or at one dose level just below, and for the proportion of patients treated at doses above the MTD. If the new method had been applied in this study, the MTD would have been reached much earlier, since, most of the time, higher dose levels were recommended. This result shows the feasibility of the new method in a two-drug setting and its use should be encouraged since fewer patients are treated at suboptimal dose levels or at dose levels above the MTD.

[1]  J. Willson,et al.  Using toxicity grades in the design and analysis of cancer phase I clinical trials. , 1992, Statistics in medicine.

[2]  M J Ratain,et al.  Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. , 1993, Journal of the National Cancer Institute.

[3]  M. Ratain,et al.  New phase I trial methodology. , 1997, Seminars in Oncology.

[4]  W. Evans Alternative Approaches for Phase I Studies of Anticancer Drugs: A Role for Therapeutic Drug Monitoring , 1993, Therapeutic Drug Monitoring.

[5]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[6]  R Simon,et al.  Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Berenbaum The expected effect of a combination of agents: the general solution. , 1985, Journal of theoretical biology.

[8]  S. Durham,et al.  A random walk rule for phase I clinical trials. , 1997, Biometrics.

[9]  M. Marty,et al.  Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. , 1993, Cancer research.

[10]  D J Kerr Phase I clinical trials: adapting methodology to face new challenges. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  E. Eisenhauer,et al.  Phase I trial design: are new methodologies being put into practice? , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M J Ratain,et al.  Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. , 1993, Journal of the National Cancer Institute.

[13]  D. Faries,et al.  Practical modifications of the continual reassessment method for phase I cancer clinical trials. , 1994, Journal of biopharmaceutical statistics.

[14]  R Simon,et al.  Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.

[15]  J O'Quigley,et al.  Continual reassessment method: a likelihood approach. , 1996, Biometrics.

[16]  S. Møller,et al.  An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. , 1995, Statistics in medicine.

[17]  B E Storer,et al.  Design and analysis of phase I clinical trials. , 1989, Biometrics.

[18]  S. Arbuck,et al.  Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  S. Piantadosi,et al.  Improved designs for dose escalation studies using pharmacokinetic measurements. , 1996, Statistics in medicine.

[20]  S. Goodman,et al.  Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.

[21]  P. Hérait,et al.  Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.